[go: up one dir, main page]

DE60105401D1 - Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit - Google Patents

Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit

Info

Publication number
DE60105401D1
DE60105401D1 DE60105401T DE60105401T DE60105401D1 DE 60105401 D1 DE60105401 D1 DE 60105401D1 DE 60105401 T DE60105401 T DE 60105401T DE 60105401 T DE60105401 T DE 60105401T DE 60105401 D1 DE60105401 D1 DE 60105401D1
Authority
DE
Germany
Prior art keywords
dopa
disease
compositions containing
renal cell
cell transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60105401T
Other languages
English (en)
Other versions
DE60105401T2 (de
Inventor
Patricio Soares-Da-Silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Publication of DE60105401D1 publication Critical patent/DE60105401D1/de
Application granted granted Critical
Publication of DE60105401T2 publication Critical patent/DE60105401T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60105401T 2000-03-14 2001-03-13 Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit Expired - Fee Related DE60105401T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0006063A GB2348371B (en) 2000-03-14 2000-03-14 Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
GB0006063 2000-03-14
PCT/EP2001/002896 WO2001068065A2 (en) 2000-03-14 2001-03-13 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
DE60105401D1 true DE60105401D1 (de) 2004-10-14
DE60105401T2 DE60105401T2 (de) 2005-10-13

Family

ID=9887552

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60105401T Expired - Fee Related DE60105401T2 (de) 2000-03-14 2001-03-13 Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit

Country Status (23)

Country Link
US (1) US20040242503A1 (de)
EP (1) EP1267853B1 (de)
JP (1) JP3677002B2 (de)
KR (1) KR100738746B1 (de)
CN (1) CN1262269C (de)
AR (1) AR035567A1 (de)
AT (1) ATE275397T1 (de)
AU (1) AU781280B2 (de)
BR (1) BR0109220A (de)
CA (1) CA2402712C (de)
CZ (1) CZ297123B6 (de)
DE (1) DE60105401T2 (de)
DK (1) DK1267853T3 (de)
ES (1) ES2228858T3 (de)
GB (1) GB2348371B (de)
HU (1) HUP0300130A3 (de)
MX (1) MXPA02009043A (de)
PL (1) PL359327A1 (de)
PT (1) PT1267853E (de)
RU (1) RU2266111C2 (de)
SI (1) SI1267853T1 (de)
TR (1) TR200402661T4 (de)
WO (1) WO2001068065A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7381772B2 (en) * 2003-12-12 2008-06-03 E. I. Du Pont De Nemours And Company Toughened poly(lactic acid) compositions
ES2390126T3 (es) * 2004-06-04 2012-11-06 Xenoport, Inc. Derivados de levodopa, y composicones y usos de la misma
EP1781094B1 (de) * 2004-07-07 2016-04-27 Kampavata AB Transgenes nichtmenschliches tier für den einsatz als forschungsmodelle für die morbus-parkinson-forschung
RU2431634C2 (ru) * 2005-03-11 2011-10-20 Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин Соединения флавоноидов и их применение
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
US20090012170A1 (en) * 2005-09-21 2009-01-08 Helena Nissinen Treatment of symptoms of motor dysfunction
EP1957109A2 (de) * 2005-12-02 2008-08-20 Sirtris Pharmaceuticals, Inc. Modulatoren von cdc2-kinasen und verfahren zu ihrer verwendung
TWI403493B (zh) 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途
US7829592B2 (en) 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
TW200843732A (en) 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
AU2008257437A1 (en) * 2007-02-14 2008-12-04 Mars, Incorporated Neurogenic compounds
BRPI0801239A2 (pt) * 2008-04-01 2009-11-17 Ache Lab Farmaceuticos Sa uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP2349973A2 (de) 2008-10-20 2011-08-03 XenoPort, Inc. Verfahren zur synthese einer levodopa ester-prodrug
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
CN105902535A (zh) * 2009-04-13 2016-08-31 中国医学科学院药物研究所 黄芩素在制备预防和治疗帕金森病药物中的应用
RU2537137C2 (ru) 2009-11-09 2014-12-27 Ксенопорт, Инк. Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102755312A (zh) * 2012-07-16 2012-10-31 中国科学院大连化学物理研究所 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
CN103211832A (zh) * 2013-04-24 2013-07-24 无锡艾德美特生物科技有限公司 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途
CN104116730A (zh) * 2013-04-26 2014-10-29 中国科学院大连化学物理研究所 二氢杨梅素作为活性成份在制备帕金森症治疗药物中的应用
KR101583399B1 (ko) * 2013-10-22 2016-01-08 충북대학교 산학협력단 아사리닌 또는 (-)-세사민을 함유하는 파킨슨병 예방 또는 치료용 약학조성물
EP3275433A1 (de) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Zusammensetzung mit verzögerter freisetzung mit mikronisiertem tolcapon
KR102681552B1 (ko) * 2016-09-27 2024-07-04 (주)아모레퍼시픽 소장 상피세포에서의 카테킨 흡수 증진제
CN111329853A (zh) * 2020-04-21 2020-06-26 遵义医科大学 一种治疗帕金森病的药物组合物及其应用和治疗帕金森病的药物
CN116908319A (zh) * 2023-05-31 2023-10-20 苏州和合医学检验有限公司 一种检测血液中苄丝肼浓度的方法
CN119192117B (zh) * 2024-10-31 2025-09-26 贵州医科大学 一种从马尾松松塔内分离出的黄酮类化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) * 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
JPS6450877A (en) * 1987-08-20 1989-02-27 Ichimaru Pharcos Inc Oxygen radical catching and removing agent
JPH035423A (ja) * 1989-06-01 1991-01-11 Ichimaru Pharcos Co Ltd フラボノイド含有過酸化脂質生成抑制剤
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
JPH09241637A (ja) * 1996-03-14 1997-09-16 Chugai Pharmaceut Co Ltd 活性酸素ラジカル除去用組成物およびその方法
GB9702310D0 (en) * 1997-02-05 1997-03-26 Univ Hertfordshire Invention
US6537969B1 (en) * 1997-10-24 2003-03-25 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
JPH11323326A (ja) * 1998-02-06 1999-11-26 Nagaoka Koryo Kk 活性酸素消去剤、皮膚保全剤および変色防止剤
FR2787319B1 (fr) * 1998-12-22 2002-06-14 Oreal Utilisation d'hydroxystilbenes pour la teinture, composition prete a l'emploi les contenant et procede de teinture
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CN101822676A (zh) * 2002-01-28 2010-09-08 协和发酵麒麟株式会社 治疗运动疾病患者的方法

Also Published As

Publication number Publication date
EP1267853B1 (de) 2004-09-08
ES2228858T3 (es) 2005-04-16
SI1267853T1 (en) 2005-04-30
JP2003526658A (ja) 2003-09-09
ATE275397T1 (de) 2004-09-15
CZ20023348A3 (cs) 2003-02-12
AU781280B2 (en) 2005-05-12
JP3677002B2 (ja) 2005-07-27
DE60105401T2 (de) 2005-10-13
CN1262269C (zh) 2006-07-05
RU2266111C2 (ru) 2005-12-20
AU5828301A (en) 2001-09-24
MXPA02009043A (es) 2004-08-19
CN1429109A (zh) 2003-07-09
PL359327A1 (en) 2004-08-23
TR200402661T4 (tr) 2004-11-22
PT1267853E (pt) 2004-12-31
KR20030095184A (ko) 2003-12-18
HUP0300130A2 (en) 2003-05-28
EP1267853A2 (de) 2003-01-02
US20040242503A1 (en) 2004-12-02
GB2348371A (en) 2000-10-04
AR035567A1 (es) 2004-06-16
CA2402712C (en) 2005-05-17
KR100738746B1 (ko) 2007-07-12
BR0109220A (pt) 2003-03-18
CA2402712A1 (en) 2001-09-20
GB0006063D0 (en) 2000-05-03
WO2001068065A2 (en) 2001-09-20
WO2001068065A9 (en) 2002-07-18
WO2001068065A3 (en) 2002-02-21
GB2348371B (en) 2001-04-04
CZ297123B6 (cs) 2006-09-13
DK1267853T3 (da) 2005-01-10
HUP0300130A3 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
DE60105401D1 (de) Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit
DE69819786D1 (de) Biozidzusammensetzungen zur behandlung vom wasser
EE200200704A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
EE200200470A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
DE60111734D1 (de) [1,4']-bipiperidin verbindungen
TR200003788A3 (tr) Yavas salimli oral dozaj bilesim.
EE200100293A (et) Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II
HUP0301069A3 (en) Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use
TR200003787A3 (tr) Kararli yavas salimli oral dozaj bilesimi.
DE60238898D1 (de) Oxidative Zusammensetzung zur Behandlung von Keratinfasern, die spezielle Aminosilikone enthält
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
ZA200301673B (en) Cathartic composition.
DK1173059T3 (da) Fremgangsmåde til forögelse af biologisk virkningsfuldhed af plantebehandlingssammensætninger
MA26041A1 (fr) Composition de fertilisants contenant du soufre et methode de leurs preparation.
NO20031273D0 (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
ATE263777T1 (de) Zusammensetzungen zur behandlung von entzündungsreaktionen
TNSN01131A1 (fr) Derives de phenoxybenzylamine nouveaux, procede pour leur preparation et compositions les contenant.
DE60131960D1 (de) Fungizide zusammensetzungen, die n-(alpha-cyano-2-thenyl)-4-ethyl-2-ethylamino-5-thiazolcarboxamide enthalten
DE60005462D1 (de) Tintenzusammensetzungen enthaltend 1,3,5-Trioxan
EE200200697A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
ATE400273T1 (de) 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)- ethylcyclohexanol-derivate als monoamin- wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen
FR2796551B1 (fr) Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
BR0012043B1 (pt) composiÇço de tratamento de cabelo.
IT1318674B1 (it) Faramaci per l'incontinenza.
AU9424601A (en) Novel aliphatic compounds, process for their preparation and their usage

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee